Assessing Comorbidities in Epilepsy Using Eye Movement Recordings
Launched by EYSZ, INC. · Mar 12, 2024
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help identify children with a type of epilepsy called childhood absence epilepsy (CAE). CAE can cause kids to have absence seizures, which are short periods where they may seem to "zone out." The goal of the study is to see if a new system that tracks eye movements can find these problems more quickly and accurately than current tests. By doing this, doctors hope to better predict ongoing seizures and any thinking difficulties that might affect a child's performance in school and daily life.
To participate in the trial, children must be diagnosed with childhood absence epilepsy by their neurologist or be healthy controls with no history of epilepsy or related disorders. The trial is open to both boys and girls, aged between 4 to 13 years old, who can speak English. Participants will undergo eye movement recordings and may also have standard tests to compare results. It’s important to note that children with certain medical conditions or vision problems may not be eligible. This study aims to improve how we detect and understand CAE, ultimately helping children lead better lives.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of Childhood Absence Epilepsy by Treating Neurologist or a Healthy control Fluent in English
- Exclusion Criteria:
- • History of subarachnoid hemorrhage, sickle cell anemia, recent cerebrovascular accident or myocardial infarction, significant cardiopulmonary disease, active asthma, known aneurysm, known moyamoya disease, or pregnancy.
- • Known diagnosis of strabismus or amblyopia Any vision abnormalities that prevent the participant from viewing the screen clearly People who have a history of generalized tonic clonic convulsions To participate as a healthy control the participant must have no personal history of epilepsy, ADHD or other developmental disorder, no first degree relatives with the above diagnosis
About Eysz, Inc.
eysz, inc. is an innovative biopharmaceutical company dedicated to advancing healthcare through the development of novel therapeutic solutions. With a focus on unmet medical needs, eysz, inc. leverages cutting-edge research and technology to drive clinical trials that aim to improve patient outcomes. The company is committed to adhering to the highest standards of clinical practice and regulatory compliance, fostering collaboration with healthcare professionals and regulatory bodies to ensure the successful translation of scientific discoveries into effective treatments. Through its robust pipeline of clinical trials, eysz, inc. strives to make a meaningful impact on the lives of patients and contribute to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Winston Salem, North Carolina, United States
Orange, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported